JP2009533356A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009533356A5 JP2009533356A5 JP2009504530A JP2009504530A JP2009533356A5 JP 2009533356 A5 JP2009533356 A5 JP 2009533356A5 JP 2009504530 A JP2009504530 A JP 2009504530A JP 2009504530 A JP2009504530 A JP 2009504530A JP 2009533356 A5 JP2009533356 A5 JP 2009533356A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- use according
- derivative
- acceptable salt
- list
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000003839 salts Chemical class 0.000 claims description 19
- 239000011780 sodium chloride Substances 0.000 claims description 19
- 206010064930 Age-related macular degeneration Diseases 0.000 claims description 11
- 208000002780 Macular Degeneration Diseases 0.000 claims description 11
- 241000124008 Mammalia Species 0.000 claims description 10
- 239000002184 metal Substances 0.000 claims description 10
- 229910052751 metal Inorganic materials 0.000 claims description 10
- 208000002492 Retinal Drusen Diseases 0.000 claims description 5
- 229910052802 copper Inorganic materials 0.000 claims description 5
- RYGMFSIKBFXOCR-UHFFFAOYSA-N copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims description 5
- 239000010949 copper Substances 0.000 claims description 5
- 201000007737 retinal degeneration Diseases 0.000 claims description 5
- HCHKCACWOHOZIP-UHFFFAOYSA-N zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 5
- 229910052725 zinc Inorganic materials 0.000 claims description 5
- 239000011701 zinc Substances 0.000 claims description 5
- 230000002730 additional Effects 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 150000001875 compounds Chemical class 0.000 claims 4
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US79227806P | 2006-04-14 | 2006-04-14 | |
US60/792,278 | 2006-04-14 | ||
PCT/AU2007/000490 WO2007118276A1 (en) | 2006-04-14 | 2007-04-13 | Method of treatment of age-related macular degeneration(amd) |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2009533356A JP2009533356A (ja) | 2009-09-17 |
JP2009533356A5 true JP2009533356A5 (da) | 2011-04-21 |
JP5290147B2 JP5290147B2 (ja) | 2013-09-18 |
Family
ID=38608967
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2009504530A Expired - Fee Related JP5290147B2 (ja) | 2006-04-14 | 2007-04-13 | 加齢黄斑変性症(amd)の処置方法 |
Country Status (14)
Country | Link |
---|---|
US (3) | US20100144693A1 (da) |
EP (2) | EP2514423A3 (da) |
JP (1) | JP5290147B2 (da) |
KR (2) | KR20100110396A (da) |
CN (3) | CN102225930A (da) |
AU (2) | AU2007240120A1 (da) |
BR (2) | BRPI0710737A2 (da) |
CA (1) | CA2683756A1 (da) |
DK (1) | DK2012789T3 (da) |
ES (1) | ES2437997T3 (da) |
IL (1) | IL207495A (da) |
NZ (2) | NZ572591A (da) |
WO (1) | WO2007118276A1 (da) |
ZA (2) | ZA200809493B (da) |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2002950217A0 (en) | 2002-07-16 | 2002-09-12 | Prana Biotechnology Limited | 8- Hydroxy Quinoline Derivatives |
ES2441873T3 (es) | 2005-05-26 | 2014-02-06 | Aldexa Therapeutics, Inc. | Derivados de quinolina para el tratamiento de enfermedades retinianas |
CN101589026B (zh) * | 2006-06-22 | 2013-10-16 | 普拉纳生物技术有限公司 | 治疗脑神经胶质瘤的方法 |
CA2737219C (en) * | 2008-08-11 | 2017-02-28 | Tracy Keller | Halofuginone analogs for inhibition of trna synthetases and uses thereof |
US8889695B2 (en) | 2008-12-24 | 2014-11-18 | Prana Biotechnology Limited | Quinazolinone compounds |
BRPI0920492A2 (pt) | 2009-01-26 | 2019-07-09 | Lawrence Dunaief Joshua | uso de deferiprona para o tratamento e prevenção de doenças oftalmológicas relacionadas ao ferro. |
CA2782015C (en) | 2009-12-11 | 2020-08-25 | Neuron Systems, Inc. | Topical ophthalmic compositions and methods for the treatment of macular degeneration |
WO2012122534A2 (en) | 2011-03-10 | 2012-09-13 | The Trustees Of Columbia University In The City Of New York | N-quinolin-benzensulfonamides and related compounds for the treatment of cancer, autoimmune disorders and inflammation |
AU2013207796B2 (en) | 2012-01-13 | 2017-04-27 | President And Fellows Of Harvard College | Halofuginol derivatives and their use in cosmetic and pharmaceutical compositions |
CN105073714A (zh) | 2012-12-20 | 2015-11-18 | 奥尔德拉医疗公司 | 迫位原醇 |
EP2948149A4 (en) | 2013-01-23 | 2016-12-14 | Aldeyra Therapeutics Inc | BY TOXIC ALDEHYDIC DISEASES AND TREATMENT |
WO2014116593A1 (en) | 2013-01-25 | 2014-07-31 | Aldexa Therapeutics, Inc. | Novel traps in the treatment of macular degeneration |
CA2968090A1 (en) | 2014-12-02 | 2016-06-09 | Prana Biotechnology Limited | 4h-pyrido[1,2-a]pyrimidin-4-one compounds |
KR102052168B1 (ko) * | 2015-04-29 | 2019-12-04 | 주식회사 트리아펙스 | 편광 필름, 이의 제조 방법, 및 이를 포함하는 편광 렌즈 |
WO2017027064A1 (en) * | 2015-08-12 | 2017-02-16 | The General Hospital Corporation | 8-hydroxyquinoline derivatives as diagnostic and therapeutic agents |
KR102664994B1 (ko) | 2015-08-21 | 2024-05-13 | 알데이라 테라퓨틱스, 아이엔씨. | 중수소화 화합물 및 이의 용도 |
WO2017053696A2 (en) * | 2015-09-24 | 2017-03-30 | University Of Florida Research Foundation, Incorporated | Halogenated quinoline derivatives as antimicrobial agents |
AU2017264697A1 (en) | 2016-05-09 | 2018-11-22 | Aldeyra Therapeutics, Inc. | Combination treatment of ocular inflammatory disorders and diseases |
EP3478288A4 (en) * | 2016-07-01 | 2020-03-04 | Prana Biotechnology Ltd | METHOD FOR TREATING IMMUNGLOBULIN LIGHT CHAIN AMYLOIDOSIS |
CN110431130A (zh) | 2017-03-16 | 2019-11-08 | 奥尔德拉医疗公司 | 多晶型化合物和其用途 |
US11040039B2 (en) | 2017-10-10 | 2021-06-22 | Aldeyra Therapeutics, Inc. | Treatment of inflammatory disorders |
EP3801525A4 (en) | 2018-06-08 | 2022-03-23 | The General Hospital Corporation | PROLYL-ARNT-SYNTHETASE INHIBITORS |
WO2020033344A1 (en) | 2018-08-06 | 2020-02-13 | Aldeyra Therapeutics, Inc. | Polymorphic compounds and uses thereof |
CN109232396B (zh) * | 2018-11-27 | 2020-07-03 | 聊城大学 | 酰胺吡啶类衍生物及其用途 |
CN113784954A (zh) | 2019-05-02 | 2021-12-10 | 奥尔德拉医疗公司 | 多晶型化合物和其用途 |
WO2022006439A2 (en) * | 2020-07-02 | 2022-01-06 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Compound embodiments for treating retinal degeneration and method embodiments of making and using the same |
CN113214249B (zh) * | 2021-04-23 | 2023-09-19 | 成都大学 | 吡啶并[1,2-a]嘧啶-4-硫酮化合物的合成方法 |
Family Cites Families (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BE505711A (da) | 1950-09-09 | |||
US4160452A (en) | 1977-04-07 | 1979-07-10 | Alza Corporation | Osmotic system having laminated wall comprising semipermeable lamina and microporous lamina |
US4256108A (en) | 1977-04-07 | 1981-03-17 | Alza Corporation | Microporous-semipermeable laminated osmotic system |
HU178910B (en) * | 1977-08-19 | 1982-07-28 | Chinoin Gyogyszer Es Vegyeszet | Process for preparing 2,3-disubstituted-4-oxo-4h-pyrido/1,2-a/-pyrimidines |
US4265874A (en) | 1980-04-25 | 1981-05-05 | Alza Corporation | Method of delivering drug with aid of effervescent activity generated in environment of use |
IT1204612B (it) | 1987-05-14 | 1989-03-10 | Bioresearch Spa | Pteridine atte alla preparazione di composizioni farmaceutiche ad attivita' antiamnesica |
US5314909A (en) * | 1993-03-17 | 1994-05-24 | Merck & Co., Inc. | Use of non-steroidal antiiflammatory agents in macular degeneration |
ES2093529T3 (es) | 1993-04-08 | 1996-12-16 | Ideal Standard | Valvula de agua sanitaria. |
US5631373A (en) | 1993-11-05 | 1997-05-20 | State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University And The University Of Oregon, Eugene Oregon | Alkyl, azido, alkoxy, and fluoro-substituted and fused quinoxalinediones |
GB9404485D0 (en) | 1994-03-09 | 1994-04-20 | Cancer Res Campaign Tech | Benzamide analogues |
DE4418096A1 (de) * | 1994-05-24 | 1995-11-30 | Cassella Ag | Verwendung von Pteridin-Derivaten als Hemmstoffe der NO-Synthase |
US6168776B1 (en) | 1994-07-19 | 2001-01-02 | University Of Pittsburgh | Alkyl, alkenyl and alkynyl Chrysamine G derivatives for the antemortem diagnosis of Alzheimer's disease and in vivo imaging and prevention of amyloid deposition |
US5801183A (en) | 1995-01-27 | 1998-09-01 | State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University And The University Of Oregon | Aza and aza (N-oxy) analogs of glycine/NMDA receptor antagonists |
HUP9903906A3 (en) | 1996-08-13 | 2001-01-29 | Gerolymatos P N Sa | Use of chelating agent clioquinol for the manufacture of a pharmaceutical composition for the treatment of alzheimer's disease |
GB9702701D0 (en) | 1997-02-01 | 1997-04-02 | Univ Newcastle Ventures Ltd | Quinazolinone compounds |
US5939421A (en) | 1997-07-01 | 1999-08-17 | Signal Pharmaceuticals, Inc. | Quinazoline analogs and related compounds and methods for treating inflammatory conditions |
US20020025944A1 (en) * | 2000-04-28 | 2002-02-28 | Bush Ashley I. | Use of clioquinol for the therapy of Alzheimer's disease |
US6337332B1 (en) * | 1998-09-17 | 2002-01-08 | Pfizer Inc. | Neuropeptide Y receptor antagonists |
AP2001002103A0 (en) | 1998-10-22 | 2001-03-31 | Neurosearch As | Substituted phenyl derivatives, their preparation and use. |
US6369058B1 (en) * | 1999-02-04 | 2002-04-09 | New Millennium Pharmaceutical Research Inc. | Brain delivery of folic acid for the prevention of alzheimer's disease and stroke |
WO2001016114A2 (en) | 1999-08-27 | 2001-03-08 | Chemocentryx, Inc. | Heterocyclic compounds and methods for modulating cxcr3 function |
AUPR201600A0 (en) | 2000-12-11 | 2001-01-11 | Fujisawa Pharmaceutical Co., Ltd. | Quinazolinone derivative |
EP1345922B1 (en) | 2000-12-21 | 2006-05-31 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
FR2819187A1 (fr) * | 2001-01-10 | 2002-07-12 | Michel Xilinas | Utilisation des substances chelatrices pour le traitement et la prevention de la deferrescence oculaire |
DE60231868D1 (de) | 2001-04-24 | 2009-05-20 | Purdue Research Foundation | Folat-mimetika und deren folatrezeptorbindende konjugate |
FR2827599A1 (fr) | 2001-07-20 | 2003-01-24 | Neuro3D | Composes derives de quinoleine et quinoxaline,preparation et utilisations |
JP2005504770A (ja) | 2001-08-17 | 2005-02-17 | メルク エンド カムパニー インコーポレーテッド | 5−スルホンアミド−8−ヒドロキシ−1,6−ナフチリジン−7−カルボキサミドの製造方法 |
JP4470219B2 (ja) | 2002-02-20 | 2010-06-02 | 味の素株式会社 | 新規フェニルアラニン誘導体 |
DE60336901D1 (de) | 2002-03-07 | 2011-06-09 | X Ceptor Therapeutics Inc | Chinazolinon modulatoren von nukleinrezeptoren |
AU2002950217A0 (en) * | 2002-07-16 | 2002-09-12 | Prana Biotechnology Limited | 8- Hydroxy Quinoline Derivatives |
AU2002951868A0 (en) * | 2002-10-04 | 2002-10-24 | Prana Biotechnology Limited | Compound i |
CA2500952C (en) * | 2002-10-04 | 2011-04-26 | Prana Biotechnology Limited | Neurologically-active compounds |
AU2004226876A1 (en) * | 2003-04-03 | 2004-10-14 | Prana Biotechnology Ltd | Treatment of neurological conditions |
EP1644325A2 (en) * | 2003-06-23 | 2006-04-12 | Neurochem (International) Limited | Methods and compositions for treating amyloid-related diseases |
NZ551004A (en) * | 2004-04-02 | 2010-07-30 | Prana Biotechnology Ltd | Neurologically-active compounds |
US20110020237A1 (en) * | 2005-01-14 | 2011-01-27 | Glabe Charles G | Compositions and Methods for Inhibiting Drusen Formation and for Diagnosing or Treating Drusen-Related Disorders |
US20080207673A1 (en) * | 2005-05-04 | 2008-08-28 | Michel Xilinas | Method for Treating Cancer, Coronary, Inflammatory and Macular Disease, Combining the Modulation of Zinc-and/or Copper Dependent Proteins |
CN101589026B (zh) * | 2006-06-22 | 2013-10-16 | 普拉纳生物技术有限公司 | 治疗脑神经胶质瘤的方法 |
-
2007
- 2007-04-13 EP EP12176495A patent/EP2514423A3/en not_active Withdrawn
- 2007-04-13 BR BRPI0710737-4A patent/BRPI0710737A2/pt not_active IP Right Cessation
- 2007-04-13 BR BRPI0722382-0A patent/BRPI0722382A2/pt not_active Application Discontinuation
- 2007-04-13 WO PCT/AU2007/000490 patent/WO2007118276A1/en active Application Filing
- 2007-04-13 KR KR1020107020805A patent/KR20100110396A/ko not_active Application Discontinuation
- 2007-04-13 AU AU2007240120A patent/AU2007240120A1/en not_active Abandoned
- 2007-04-13 ZA ZA200809493A patent/ZA200809493B/xx unknown
- 2007-04-13 ES ES07718737.5T patent/ES2437997T3/es active Active
- 2007-04-13 CA CA002683756A patent/CA2683756A1/en not_active Abandoned
- 2007-04-13 CN CN2011101585377A patent/CN102225930A/zh active Pending
- 2007-04-13 JP JP2009504530A patent/JP5290147B2/ja not_active Expired - Fee Related
- 2007-04-13 CN CN2010102559981A patent/CN101987849B/zh not_active Expired - Fee Related
- 2007-04-13 US US12/297,165 patent/US20100144693A1/en not_active Abandoned
- 2007-04-13 CN CNA2007800222734A patent/CN101534826A/zh active Pending
- 2007-04-13 NZ NZ572591A patent/NZ572591A/en not_active IP Right Cessation
- 2007-04-13 EP EP07718737.5A patent/EP2012789B1/en not_active Not-in-force
- 2007-04-13 DK DK07718737.5T patent/DK2012789T3/da active
- 2007-04-13 KR KR1020087027935A patent/KR20080109096A/ko not_active Application Discontinuation
- 2007-04-13 NZ NZ590271A patent/NZ590271A/en unknown
-
2010
- 2010-07-30 AU AU2010206074A patent/AU2010206074B2/en not_active Ceased
- 2010-08-09 IL IL207495A patent/IL207495A/en active IP Right Grant
- 2010-08-19 ZA ZA2010/05922A patent/ZA201005922B/en unknown
- 2010-11-23 US US12/952,425 patent/US20110071167A1/en not_active Abandoned
-
2013
- 2013-11-22 US US14/087,689 patent/US9163018B2/en not_active Expired - Fee Related
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2009533356A5 (da) | ||
JP2009513713A5 (da) | ||
WO2011014255A8 (en) | Treatment of crohn's disease with laquinimod | |
JP2014506321A5 (da) | ||
JP2008534503A5 (da) | ||
JP2015505564A5 (da) | ||
JP2012184234A5 (da) | ||
JP2008534453A5 (da) | ||
JP2015025011A5 (da) | ||
RU2012145116A (ru) | Фармацевтическая композиция для предупреждения или лечения неалкогольного жирового гепатоза и способ предупреждения или лечения неалкогольного жирового гепатоза с ее использованием | |
JP2015523546A5 (da) | ||
JP2014505107A5 (da) | ||
JP2008540528A5 (da) | ||
JP2007530703A5 (da) | ||
JP2015522018A5 (da) | ||
JP2023116697A5 (da) | ||
EP4353317A3 (en) | Ret inhibitor for use in treating cancer having a ret alteration | |
JP2007504168A5 (da) | ||
JP2008543853A5 (da) | ||
WO2008070010A3 (en) | Hydroxylamine derivatives for the treatment of stroke | |
JP2014513065A5 (da) | ||
JP2018525447A5 (da) | ||
JP2019529569A5 (da) | ||
JP2012526099A5 (da) | ||
JP2013502449A5 (da) |